Figure 3. Serum Levels of Bone Turnover Markers.

A, At the end of the first year, there was no significant difference regarding C-terminal telopeptide (CTX) serum levels between the positive control (group A) and the treatment group (group ZOL, which combines groups B, C, and D). B, Compared with group A, the ZOL subgroup with 3 or more years of denosumab treatment at baseline had a significant difference in CTX serum levels at the end of the first year. No significant difference was observed for the ZOL subgroup with a shorter duration of denosumab treatment (<3 years). C, N-terminal propeptide of type 1 collagen (P1NP) serum levels increased significantly at the end of the first year in group ZOL. D, Both subgroups had significant differences in P1NP serum levels compared with group A.